Terminated, withdrawn and suspended trials

clinicaltrialsObservedShowing 801–850 of 1,232 studies, most recently updated first

NCT	Title	Phase	Status	First posted	Lead sponsor	Why stopped (as posted)	Category
NCT02986451	Clarithromycin,Lenalidomide and Dexamethasone for Relapsed/Refractory Myeloma	Phase 2	withdrawn	Dec 8, 2016	Sun Yat-sen University	not stated	Not stated
NCT03227432	An Exploratory Study to Evaluate the Combination of Elotuzumab and Nivolumab With and…	Phase 2	withdrawn	Jul 24, 2017	Dana-Farber Cancer Institute	Withdrawn before enrollment due to issues around the FDA hold on PD-1/PD-L1 drugs in combination…	Enrollment / accrual
NCT02702141	A Safety Study of SGN-CD19B in Patients With B-cell Non-Hodgkin Lymphoma	Phase 1	terminated	Mar 8, 2016	Seagen Inc.	not stated	Not stated
NCT00012298	Radiolabeled Monoclonal Antibody Plus Rituximab With and Without Filgrastim and…	Phase 1 / Phase 2	terminated	Jan 27, 2003	National Cancer Institute (NCI)	Trial completed prematurely.	Other (stated, no rule matched)
NCT00124579	S0417 Bortezomib, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or…	Phase 2	terminated	Jul 28, 2005	SWOG Cancer Research Network	poor accrual	Enrollment / accrual
NCT02720510	A Trial Evaluating Efficacy & Safety of RVD +/- Panobinostat in Transplant Eligible,…(PANORAMA4)	Phase 2	terminated	Mar 28, 2016	Novartis Pharmaceuticals	A study was terminated due to low enrollment.	Enrollment / accrual
NCT01761682	Acute Lymphoblastic Leukemia Registry at Asan Medical Center	—	terminated	Jan 7, 2013	Asan Medical Center	The PI resigned the institute, and the rest investigators at the institute decided to terminate the…	Other (stated, no rule matched)
NCT01779167	Thalidomide, Lenalidomide, and Rituximab for Previously Treated Waldenstrom…(THRiL for WM)	Phase 2	terminated	Jan 30, 2013	Weill Medical College of Cornell University	Slow Accrual	Enrollment / accrual
NCT01484626	Bendamustine, Wkly Bortezomib, Lenalidomide and Dexamethasone for Multiple Myeloma(BVRD)	Phase 1 / Phase 2	terminated	Dec 2, 2011	Loyola University	Celgene would no longer supply lenalidomide for the study	Drug supply
NCT02168907	CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or…	Phase 1	terminated	Jun 20, 2014	Wake Forest University Health Sciences	Slow Accruals	Enrollment / accrual
NCT02971410	Simvastatin in Overcoming Chemotherapy Resistance in Patients With Relapsed or Refractory…	Early Phase 1	withdrawn	Nov 23, 2016	Wake Forest University Health Sciences	PI no longer interested in pursuing study.	Other (stated, no rule matched)
NCT01050764	Haploidentical Allogeneic Transplant With Post-transplant Infusion of Regulatory T-cells	Phase 1 / Phase 2	terminated	Jan 15, 2010	Everett Meyer	Safety	Safety / toxicity
NCT01925612	Study of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of…	Phase 2	terminated	Aug 20, 2013	Seagen Inc.	Sponsor decision based on portfolio prioritization and changing treatment landscape in frontline…	Sponsor / business decision
NCT00664378	Efficacy Study of CYT997 in Multiple Myeloma	Phase 2	terminated	Apr 22, 2008	Gilead Sciences	Difficulty enrolling patients	Enrollment / accrual
NCT00538824	Phase II Study of Dexamethasone, Thalidomide and Lenalidomide for Subjects With Relapsed…(DexTR)	Phase 2	terminated	Oct 3, 2007	Weill Medical College of Cornell University	low enrollment	Enrollment / accrual
NCT01812005	Alisertib With and Without Rituximab in Treating Patients With Relapsed or Refractory…	Phase 2	terminated	Mar 15, 2013	Ohio State University Comprehensive Cancer Center	Slow patient enrollment and study discontinued after 14 patients enrolled	Enrollment / accrual
NCT01979276	Study of Pomalidomide, Dexamethasone, and Romidepsin for Rel/Ref Myeloma(Romi Poma)	Phase 1 / Phase 2	terminated	Nov 8, 2013	Weill Medical College of Cornell University	this study was terminated due to losing financial support, and enrollment challenges	Enrollment / accrual
NCT02420210	Bendamustine, Obinutuzumab, and Dexamethasone in Older Patients With Diffuse Large B-cell…	Phase 2	terminated	Apr 17, 2015	University of Chicago	Trials was stopped early due to lack of funding.	Funding
NCT01174082	Trial of ID-Specific Donor Vaccinated Lymphocyte Infusion for Patients With Myeloma…	Phase 2	terminated	Aug 3, 2010	M.D. Anderson Cancer Center	Slow Accrual	Enrollment / accrual
NCT03023527	Nivolumab Role in the Treatment of Patients With Refractory or Relapse Multiple Myeloma	Phase 1	terminated	Jan 18, 2017	PETHEMA Foundation	Safety	Safety / toxicity
NCT00482053	Phase 2 Poor Risk DLBCL of TLI and ATG Followed by Matched Allogeneic HT as Consolidation…	Phase 2	terminated	Jun 4, 2007	Stanford University	Low accrual	Enrollment / accrual
NCT02985333	Paclitaxel,Cyclophosphamide and Dexamethasone for Relapsed or Refractory Multiple Myeloma	Phase 2	withdrawn	Dec 7, 2016	Sun Yat-sen University	not stated	Not stated
NCT02372240	A Study of VLX1570 and Dexamethasone in Myeloma Patients	Phase 1 / Phase 2	terminated	Feb 26, 2015	Vivolux AB	Dose limiting tox is observed. Study put on full clinical hold.	Other (stated, no rule matched)
NCT00290407	Rituximab Plus Beta-Glucan in Chronic Lymphocytic Leukemia(CLL)/Small Lymphocytic…	Phase 2	terminated	Feb 13, 2006	University of Louisville	terminated due to lack of accrual	Enrollment / accrual
NCT00984165	Pilot Study of Radiation-Enhanced Allogeneic Cell Therapy for Progressive Hematologic…	Phase 2	terminated	Sep 25, 2009	National Cancer Institute (NCI)	Terminated due to slow accrual, PI left NIH and primary endpoint not met.	Investigator
NCT02877082	Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood…	Phase 2	terminated	Aug 24, 2016	Emory University	not stated	Not stated
NCT00906841	Study of 90Y-DOTA-hLL2 as a Consolidation Therapy After R-CHOP in Patients With Diffuse…	Phase 2	terminated	May 21, 2009	French Innovative Leukemia Organisation	completed recruitment of patients on 15 december 2010	Enrollment / accrual
NCT01612988	Treatment With Bendamustine, Ofatumumab and MethylPrednisolone in Relapsed B-CLL(BOMP)	Phase 2	terminated	Jun 6, 2012	French Innovative Leukemia Organisation	Other drugs others studies	Other (stated, no rule matched)
NCT00626626	Clofarabine and Non-Myeloablative Allogeneic Hematopoietic Transplantation	Phase 1 / Phase 2	terminated	Feb 29, 2008	Milton S. Hershey Medical Center	Investigator decision	Investigator
NCT01382615	Protocol to Obtain Blood and Bone Marrow Samples for Myeloma Research	—	terminated	Jun 27, 2011	Dartmouth-Hitchcock Medical Center	Unable to fill cohort	Other (stated, no rule matched)
NCT02155634	Continuous Lenalidomide Therapy Versus Observation Following Induction Without…	Phase 3	withdrawn	Jun 4, 2014	Celgene	The study was terminated due to poor feasibility and lack of interest at the participating sites.	Other (stated, no rule matched)
NCT02732925	To Compare Conservative Management Vs. Balloon Kyphoplasty in the Treatment of VCFs in…(MELODY)	N/A	terminated	Apr 11, 2016	Royal National Orthopaedic Hospital NHS Trust	Difficulties with recruitment due to change in referral rates.	Enrollment / accrual
NCT02020109	Evaluation of Splenic Irradiation in Chronic Lymphatic Leukemia	—	withdrawn	Dec 24, 2013	Maastricht Radiation Oncology	Logistics and financial	Funding
NCT00909948	Intentional Rejection of the Donor Graft Using Recipient Leukocyte Infusion(s) Following…(RLI)	Phase 1	terminated	May 29, 2009	Massachusetts General Hospital	Slow Accrual	Enrollment / accrual
NCT01271010	A Study of Rituximab in Combination With Fludarabine and Cyclophosphamide in Participants…	Phase 4	terminated	Jan 6, 2011	Hoffmann-La Roche	not stated	Not stated
NCT01069432	Protocol to Obtain Blood for Discovery of Novel Biomarkers and Potential Therapeutic…	—	withdrawn	Feb 17, 2010	Dartmouth-Hitchcock Medical Center	IRB delayed their review for an extensive period of time. Funding for this protocol is no longer…	Funding
NCT02488512	Peptide Receptor Radionuclide Therapy With 90Y-Dotatoc in Relapsed/Refractory Diffuse…(itTRIOlym)	Phase 2	terminated	Jul 2, 2015	Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS	critical low recruitment rate	Enrollment / accrual
NCT02530125	Pidilizumab in Treating Patients With Stage III-IV Diffuse Large B-Cell Lymphoma…	Phase 2	terminated	Aug 20, 2015	Northwestern University	sponsor decided to discontinue development of the study drug.	Sponsor / business decision
NCT00113646	Non-Myeloablative HLA-Mismatched Ex-Vivo T-cell Depleted Stem Cell Transplantation for…	Phase 2	terminated	Jun 10, 2005	Massachusetts General Hospital	Expiration of MEDI-507	Other (stated, no rule matched)
NCT00113828	Non-Myeloablative HLA-Matched Ex-Vivo T-cell Depleted Stem Cell Transplantation for…	Phase 2	terminated	Jun 13, 2005	Massachusetts General Hospital	Insufficient accrual	Enrollment / accrual
NCT02366663	BEAM vs. 90-Yttrium Ibritumomab Tiuxetan (Zevalin®)/BEAM With ASCT for Relapsed DLBCL(SPINOZA)	Phase 3	terminated	Feb 19, 2015	City of Hope Medical Center	Withdrawal of sponsor support	Other (stated, no rule matched)
NCT01313611	BRIEF Bendamustine and Rituximab In Elderly Follicular(BRIEF)	Phase 2	terminated	Mar 14, 2011	The Lymphoma Academic Research Organisation	Treament with rituximab during maintenance phase was stoped, according to DSMC recommendations,…	Other (stated, no rule matched)
NCT02137889	Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VAY736 in Relapsed or…(VAY736Y)	Phase 1	terminated	May 14, 2014	Novartis Pharmaceuticals	Study terminated on 04Oct2013 for business reasons after being on hold for 10 months. Early…	Safety / toxicity
NCT02371590	Lenalidomide and Obinutuzumab for Previously Untreated CLL	Phase 2	withdrawn	Feb 25, 2015	University of California, San Diego	Study Not Activated Due to Contract Issues	Other (stated, no rule matched)
NCT01147393	Combination Veltuzumab and Fractionated 90Y- Epratuzumab Radioimmunotherapy in Follicular…	Phase 1 / Phase 2	terminated	Jun 22, 2010	Weill Medical College of Cornell University	closed to enrollment due to slow patient accrual	Enrollment / accrual
NCT01002248	Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple…	Phase 3	terminated	Oct 27, 2009	AEterna Zentaris	not stated	Not stated
NCT01315873	Bortezomib and Bendamustine to Treat Relapsed/Refractory Myeloma	Phase 2	terminated	Mar 15, 2011	NYU Langone Health	PI left the institution before all data analysis was completed	Investigator
NCT00003512	Antineoplaston Therapy in Treating Patients With Recurrent or Refractory Waldenstrom's…	Phase 2	withdrawn	Jan 27, 2003	Burzynski Research Institute	No participants enrolled	Enrollment / accrual
NCT01675141	Lenalidomide Maintenance Therapy for Multiple Myeloma	Phase 2	terminated	Aug 29, 2012	National Cancer Institute (NCI)	Original investigator left the NIH and the primary outcome was not reached	Investigator
NCT01446900	R-2cda and Prolongation of Therapy With Rituximab Alone in Chronic Lymphocytic Leukaemia…	Phase 2	terminated	Oct 5, 2011	European Institute of Oncology	low rate in patient accrual	Enrollment / accrual

Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.

Data updated 23 days agoSource updated Aug 14, 2018source: clinicaltrials

Terminated, withdrawn and suspended studies

Stated reasons by category

Classification rules